Off-label use reimbursement

Food and Drug Law Journal

Volumn 64, Issue 2, 2009, Pages 391-403

  Cohen, Joshua ^a   Wilson, Andrew ^a   Faden, Laura ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG INDICATION; DRUG LEGISLATION; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; OFF LABEL DRUG USE; ORGANIZATION AND MANAGEMENT; PHARMACY; PRESCRIPTION; REIMBURSEMENT; REVIEW; RHEUMATOID ARTHRITIS;

CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); DRUG APPROVAL; EVIDENCE-BASED MEDICINE; FORMULARIES AS TOPIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE; OFF-LABEL USE; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES;

EID: 66749109421     PISSN: 1064590X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Raiford, D.S., Shulman, S.R. & Lasagna, L. Determining Appropriate Reimbursement for Prescription Drugs: Off-label Uses and Investigational Therapies, FOOD & DRUG L J (1994), 49(1):37-76.
2. Berenson, A., Medicare Cuts Payout on Two Cancer Drugs, NY TIMES (Dec 7, 2007).
3. Laetz, T. & Silberman, G., Reimbursement Policies Constrain the Practice of Oncology, JAMA (Dec 4, 1991), 266(21):2996-2999.
4. Radley, D.C., Finkelstein, S.N. & Stafford, R.S., Off-label Prescribing Among Office-based Physicians, ARCHIVES OF INTERNAL MEDICINE (May 8, 2006), 166 (9): 1021-1026.
5. Benson, A.B., III & Brown, E., Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debate, AMERICAN HEALTH & DRUG BENEFITS, (2008), 1 (1):28-33.
6. 6 American Society of Clinical Oncology, Reimbursement for Cancer Treatment: Coverage of Off-label Drug Indications, JOURNAL OF CLINICAL ONCOLOGY (Jul. 1, 2006), 24 (19):3206-3208. (Pubitemid 46638958)
7. Cohen, J. & Wilson, A., New challenges to MedicareFighting Beneficiary Access to mAbs., MABS(2009), 1(1): 1-11.
8. Radley, D.C., Finkelstein, S.N. & Stafford, R.S., Off-label Prescribing Among Office-based Physicians, ARCHIVES OF INTERNAL MEDICINE (May 8, 2006), 166 (9):1021-1026.
9. Radley, D.C., Finkelstein, S.N. & Stafford, R.S., Off-label Prescribing Among Office-based Physicians, ARCHIVES OF INTERNAL MEDICINE (May 8, 2006), 166 (9):1021-1026.
10. Fighting Serious Illness. Amgen Annual Report (2005). http://www.amgen.com/pdfs/Investors-2005-AnnualReport.pdf, (accessed Sept. 3, 2008).
11. Off-label Use of Anticancer Therapies: Physician Prescribing Trends and the Impact of Payer Coverage Polic, Gaithersburg, MD, Covance, (Sept. 2005), http://www.bio.org/speeches/pubs/CovanceReport.pdf, (accessed Dec. 1, 2008).
12. Off-label Drugs: Reimbursement Policies Constrain Physicians in Their Choice of Cancer Therapies, Report to the Chairman, Senate Committee on Labor and Human Resources (GAO/PEMD-91-14), (Sept. 1991), http://archive.gao.gov/ d18t9/144933.pdf, (accessed Dec. 2, 2008).
13. Off-label Drugs: Reimbursement Policies Constrain Physicians in Their Choice of Cancer Therapies, Report to the Chairman, Senate Committee on Labor and Human Resources (GAO/PEMD-91-14), (Sept. 1991), http://archive.gao.gov/ d18t9/144933.pdf, (accessed Dec., 2008).
14. Off-label Use of Anticancer Therapies: Physician Prescribing Trends and the Impact of Payer Coverage Policy, Gaithersburg, MD, Covance, (Sept. 2005), http://www.bio.org/speeches/ pubs/CovanceReport.pdf, (accessed Dec. 1, 2008);
15. Off-label Drugs: Reimbursement Policies Constrain Physicians in Their Choice of Cancer Therapies, Report to the Chairman, Senate Committee on Labor and Human Resources (GAO/PEMD-91-14), (Sept. 1991). http://archive.gao. gov/d18t9/144933.pdf, (accessed Dec. 2, 2008);
16. Impact of Payer Coverage and Reimbursement Policies on Off-label Use of Anticancer Therapies, Gaithersburg, MD, Covance, (Dec. 2008), http://www.accc-cancer.org/public-policy/publicpolicy-offlabelsurveysummary.asp, (accessed Jan 8, 2009).
17. Garber, A.M., Cost-effectiveness and Evidence Evaluation as Criteria for Coverage Policy, HEALTH AFFAIRS (2004) Jan-Jun, Suppl Web Exclusives: W4-284-296.
18. ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Medication, Sixth Edition, Atlanta, GA: HHS. Centers for Disease Control and Prevention, Baltimore, MD, CMS, (2007).
19. Stern, D. & Reissman, D., Specialty Pharmacy Cost Management Strategies of Private Healthcare Payers, JOURNAL OF MANAGED CARE PHARMACY (Nov.-Dec., 2006), 12(9):736-744.
20. Lipsy, R.J., Fuller, M.G., Roski, J. & Mansukani, S., Anticipating the Future: How the Emergence of Innovative Biologic Agents Impacts Benefit Design, Utilization, and Provider Relations, JOURNAL OF MANAGED CARE PHARMACY, (May, 2004), 10(3 Suppl):S4-9;
21. Foote, S.B. & Town, R.J., Implementing Evidence-based Medicine Through Medicare Coverage Decisions, HEALTH AFFAIRS (NOV.-Dec 2007) 26(6): 1634-1642.
22. Ratner, M. & Gura, T., Off-label or Off-limits?, NATURE BIOTECHNOLOGY (Aug., 2008), 26(8):867-875.
23. Abelson, R. & Pollack, A., Medicare Widens Drugs it Accepts for Cancer, NY TIMES (Jan. 26 2009).
24. Gleeson, S., Blue Cross and Blue Shield Association's Coverage Policies. In: Proceedings of the 1990 Drug Information Association meeting "Unlabeled uses of marketed drugs," Wash., DC, (Oct. 22-23, 1990).
25. Sipkoff, M., Off-label Use Often Presents Conundrum for Health Plans, MANAGED CARE MAGAZINE, (Aug. 2006), see http://www.managedcaremag.com/archives/ 0608/0608.offlabel.html, (accessed Aug. 10, 2008).
26. Evans, B.J., What Will it Take to Reap the Clinical Benefits of Pharmacogenomics?, FOOD & DRUG LAW JOURNAL (2006), 61(4), 753-794.
27. Eichler, H.G., Pignatti, F., Flamion, B., Leufkens, H. & Breckenridge, A., Balancing Early Market Access to New Drugs With the Need for Benefit/Risk Data: A Mounting Dilemma, NATURE REVIEWS. DRUG DISCOVERY (2008), 7(10), 818-826.
28. DeAngelis, C.D. & Fontanarosa, P.B., Prescription Drugs, Products Liability, and Preemption of Tort Litigation, JAMA (Oct. 22, 2008) 300(16),1939-1941.
29. Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices, http://www.fda.gov/oc/op/goodreprint.html, (accessed Mar. 30, 2009).
30. State laws requiring third-party reimbursement for off-label uses of prescription drugs for the treatment of cancer. National Cancer Institute. State Cancer Legislative Database Program, Bethesda, MD, http://www.scld-nci.net/ Data/off-label-use-09-30-07.pdf, (accessed Aug. 3, 2008).
31. Benson, A.B., III & Brown, E., Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debat, AMERICAN HEALTH & DRUG BENEFITS, (2008), 1(1), 28-33;
32. State laws requiring third-party reimbursement for off-label uses of prescription drugs for the treatment of cancer. National Cancer Institute. State Cancer Legislative Database Program, Bethesda, MD, http://www.scld-nci. net/Data/off-label-use-09-30-07.pdf, (accessed Aug. 3, 2008);
33. Kazi, D., Rosiglitazone and Implications for Pharmacovigilance, BMJ (Jun.16, 2007), 334(7606): 1233-1234.
34. Faden, L.B., Milne, C.-P., Pharmacovigilance Activities in the United States, European Union and Japan: Harmonic Convergence or Convergent Evolution?, FOOD & DRUG LAW J, (2008) 63(3), 683-700;
35. Gottlieb, S., Opening Pandora's Pillbox: Using Modern Information Tools to Improve Drug Safety, HEALTH AFFAIRS, (Jul-Aug, 2005), 24(4):938-948.
36. Keenan, P.S., Neumann, P.J. & Phillips, K.A., Biotechnology and Medicare's New Technology Policy: Lessons From Three Case Studies, HEALTH AFFAIRS, (Sep-Oct 2006), 25(5), 1260-1269;
37. Medicare National Coverage Determinations Manual, Chapter 1, Part 4 (Sections 200-310.1), Coverage Determinations, See http://www.cms.hhs.gov/ manuals/downloads/ncd103c1-part4.pdf, (accessed Oct. 28, 2008).
38. Saul, S., Medicare Balks at Covering Johnson Heart Drug in Some Cases. NY TIMES (Dec. 2, 2005).